Subject Characteristics for groups matched for GH treatment.

BAP SDS was significantly more increased in rhGH treated patients than in the untreated children (p<0.05) (Fig. 3, Table 6). Conversely, TRAP5b SDS was significantly lower in rhGH treated patients than in untreated controls (p<0.05). Sclerostin SDS in rhGH treated patients was not different from healthy controls but significantly higher than in the matched rhGH untreated patients (p<0.005). cFGF-23 did not differ by rhGH treatment status. Subject Characteristics for groups matched for GH treatment.